CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Prescient Therapeutics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Prescient Therapeutics Ltd
L 4 100 Albert Rd
Phone: +61 396927222p:+61 396927222 SOUTH MELBOURNE, VIC  3205  Australia Ticker: PTXPTX

Business Summary
Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is engaged in the development of personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 is a compound with the ability to block a cancer growth enzyme, geranylgeranyl transferase-1 (GGT-1). PTX-100 is in Phase Ib expansion cohort study in T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. PTX-200 is in Phase Ib/II trial in relapsed and refractory AML. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M is a platform for enhancing cell therapies by producing cells with superior phenotypes. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20236/30/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board Steven B.Engle 11/28/2014 11/28/2014
Chief Executive Officer, Managing Director, Executive Director StevenYatomi-Clarke 2/15/2016 11/28/2014
Chief Financial Officer, Company Secretary Melanie J.Leydin 1/1/2022 2/3/2015
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Pathway Oncology Pty Ltd
PTX

General Information
Number of Employees: 3 (As of 12/31/2011)
Outstanding Shares: 805,319,793 (As of 12/31/2023)
Shareholders: 8,265
Stock Exchange: ASX
Fax Number: +61 390779233


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024